PharmaSGP Holding Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Natalie Weigand

Amministratore delegato

€865.0k

Compenso totale

Percentuale dello stipendio del CEO	34.7%
Mandato del CEO	4.7yrs
Proprietà del CEO	n/a
Durata media del management	4.7yrs
Durata media del Consiglio di amministrazione	4.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Natalie Weigand rispetto agli utili di PharmaSGP Holding?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	€18m
Mar 31 2024	n/a	n/a	€18m
Dec 31 2023	€865k	€300k	€16m
Sep 30 2023	n/a	n/a	€15m
Jun 30 2023	n/a	n/a	€14m
Mar 31 2023	n/a	n/a	€13m
Dec 31 2022	€314k	€250k	€12m
Sep 30 2022	n/a	n/a	€11m
Jun 30 2022	n/a	n/a	€11m
Mar 31 2022	n/a	n/a	€11m
Dec 31 2021	€272k	€250k	€11m
Sep 30 2021	n/a	n/a	€8m
Jun 30 2021	n/a	n/a	€8m
Mar 31 2021	n/a	n/a	€9m
Dec 31 2020	€279k	€258k	€11m
Sep 30 2020	n/a	n/a	€16m
Jun 30 2020	n/a	n/a	€17m
Mar 31 2020	n/a	n/a	€17m
Dec 31 2019	€141k	€141k	€17m

Compensazione vs Mercato: La retribuzione totale di Natalie ($USD 909.38K ) è circa la media per le aziende di dimensioni simili nel mercato German ($USD 1.04M ).

Compensazione vs guadagni: La retribuzione di Natalie è aumentata di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Natalie Weigand (43 yo)

4.7yrs

Mandato

€865,000

Compensazione

Ms. Natalie Weigand serves as the Chief Executive Officer at PharmaSGP Holding SE since June 2020 and also serves as a Member of Management Board since March 04, 2020. She joined the FUTRUE Group as the le...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Natalie Weigand	CEO & Member of Management Board	4.7yrs	€865.00k	Nessun dato
Michael Rudolf	CFO & Member of Management Board	4.7yrs	€879.00k	Nessun dato
Peter Gerckens	Member of Management Board	less than a year	Nessun dato	Nessun dato

4.7yrs

Durata media

Gestione esperta: Il team dirigenziale di PSG è considerato esperto (durata media dell'incarico 4.7 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Axel Rebien	Member of the Supervisory Board	4.4yrs	€50.00k	Nessun dato
Madlena Hohlefelder	Deputy Chairwoman of the Supervisory Board	4.7yrs	Nessun dato	48.95% € 147.9m
Clemens Fischer	Chairman of the Supervisory Board	4.7yrs	Nessun dato	Nessun dato

4.7yrs

Durata media

49yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PSG sono considerati esperti (durata media dell'incarico 4.7 anni).

PharmaSGP Holding Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

PharmaSGP Holding SE, Annual General Meeting, Jun 26, 2024

PharmaSGP Holding SE, Annual General Meeting, Jun 15, 2022

Recent updates

PharmaSGP Holding SE to Report Nine Months, 2024 Results on Nov 28, 2024

Second quarter 2024 earnings: EPS misses analyst expectations

PharmaSGP Holding SE to Report First Half, 2024 Results on Sep 26, 2024

Price target increased by 9.2% to €38.75

First quarter 2024 earnings released: EPS: €0.38 (vs €0.24 in 1Q 2023)

PharmaSGP Holding SE, Annual General Meeting, Jun 26, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Dividend of €1.36 announced

PharmaSGP Holding SE Proposes Dividend for the Financial Year 2023

PharmaSGP Holding SE Proposes Dividend for the Financial Year 2023

PharmaSGP Holding SE to Report Fiscal Year 2023 Results on Apr 29, 2024

Investor sentiment improves as stock rises 19%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings released: EPS: €0.33 (vs €0.25 in 2Q 2022)

Upcoming dividend of €0.49 per share at 1.7% yield

New minor risk - Financial position

Price target increased by 7.2% to €37.00

Price target increased by 9.2% to €35.50

PharmaSGP Holding SE (XTRA:PSG) commences an Equity Buyback Plan, under the authorization approved on May 28, 2020.

PharmaSGP Holding SE to Report Q1, 2022 Results on Sep 15, 2022

PharmaSGP Holding SE, Annual General Meeting, Jun 15, 2022

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

PharmaSGP Holding SE Provides Revenues Guidance for the Financial Year 2022

PharmaSGP Proposes Dividend for 2021

PharmaSGP Holding SE to Report Fiscal Year 2021 Results on Mar 15, 2022

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2021 earnings released: EPS €0.25 (vs €0.32 in 2Q 2020)

First quarter 2021 earnings released: EPS €0.10 (vs €0.27 in 1Q 2020)

PharmaSGP Holding SE Provides Earnings Guidance for 2021

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS €0.89 (vs €1.39 in FY 2019)

New 90-day low: €19.80

PharmaSGP Holding SE to Report Fiscal Year 2020 Final Results on Apr 22, 2021

Investor sentiment improved over the past week

Market pulls back on stock over the past week

New 90-day low: €26.90

New 90-day low: €29.10

First half earnings released

PharmaSGP Holding SE to Report First Half, 2020 Final Results on Sep 30, 2020

PharmaSGP Holding SE to Report First Half, 2020 Results on Sep 10, 2020

PharmaSGP Holding SE to Report Q3, 2020 Results on Nov 30, 2020

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media